Status:
TERMINATED
Nozin in Preventing Respiratory Viral Infections in Patients Undergoing Stem Cell Transplant, PREV-NOSE STUDY
Lead Sponsor:
Fred Hutchinson Cancer Center
Collaborating Sponsors:
Global Life Technologies Corp.
Conditions:
Hematopoietic and Lymphoid Cell Neoplasm
Malignant Solid Neoplasm
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
This phase I trial studies the side effects of Nozin in preventing respiratory viral infections in patients undergoing stem cell transplant. Nozin is a non-antibiotic, alcohol-based nasal sanitizer us...
Detailed Description
OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: Beginning 7 days prior to transplant, patients receive Nozin via nasal single-use popswabs or single-use cotton tipped applicators and swab the...
Eligibility Criteria
Inclusion
- Undergoing allogeneic hematopoietic transplant for malignant or non-malignant disease
- English speaking
- Capable of providing informed consent
- Planned to receive follow-up at the transplant site for the first 100 days post transplantation
- Subjects who the investigator believes can and will comply with the study protocol
Exclusion
- Documented respiratory viral infection in the two weeks prior to enrollment
- Current or planned use of any prophylactic antiviral therapy, antibody treatments, or other agents targeting the prevention of respiratory viruses (i.e. oseltamivir, ribavirin, amantadine)
- Known allergy to study drug components (jojoba, orange oil, coconut oil, lauric acid, benzalkonium chloride, vitamin E)
- Receiving oxygen supplementation at time of enrollment
- Active mucositis at time of enrollment
- Ongoing irritation or active infection of the squamous epithelial cell skin involving the nose or nasal vestibule
- Daily use of nasal decontamination products or other nasal medications (e.g. nasal steroids)
- Unable to complete study procedures (e.g. nasal swab self-testing)
Key Trial Info
Start Date :
September 3 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 12 2020
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT04060849
Start Date
September 3 2019
End Date
April 12 2020
Last Update
November 8 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Chicago Medicine-Orland Park
Orland Park, Illinois, United States, 60462
2
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, United States, 98109